Financhill
Sell
31

DBVT Quote, Financials, Valuation and Earnings

Last price:
$3.22
Seasonality move :
-5.3%
Day range:
$2.95 - $3.19
52-week range:
$2.20 - $10.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.21x
Volume:
21.5K
Avg. volume:
251.9K
1-year change:
-66.77%
Market cap:
$65.4M
Revenue:
--
EPS (TTM):
-$5.25

Analysts' Opinion

  • Consensus Rating
    DBV Technologies SA has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of --, DBV Technologies SA has an estimated upside of 590.04% from its current price of $3.19.
  • Price Target Downside
    According to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.19.

Fair Value

  • According to the consensus of 0 analysts, DBV Technologies SA has 590.04% upside to fair value with a price target of -- per share.

DBVT vs. S&P 500

  • Over the past 5 trading days, DBV Technologies SA has underperformed the S&P 500 by -8.83% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • DBV Technologies SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • DBV Technologies SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter DBV Technologies SA reported revenues of --.

Earnings Growth

  • DBV Technologies SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter DBV Technologies SA reported earnings per share of -$1.60.
Enterprise value:
19.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$73M -$102.5M -$104.8M -$18.3M -$30.3M
EBITDA -$63.3M -$83M -$96.8M -$15.7M -$28.6M
Diluted EPS -$5.40 -$5.50 -$5.25 -$0.85 -$1.60
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets -- $110.1M $225.7M $169.3M $68.8M
Total Assets -- $170.9M $248.1M $189.8M $93.1M
Current Liabilities -- $33.8M $28.4M $31.4M $30.9M
Total Liabilities -- $54M $36.1M $45.8M $39M
Total Equity -- $116.9M $212.1M $144M $54M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$50.6M -$89.9M -$105.9M -$19.6M -$22.5M
Cash From Investing -$540K -$655K -$1.7M -$322K -$109K
Cash From Financing $194.8M $6.7M -$277K -$837K $7K
Free Cash Flow -$52.2M -$90.2M -$108.7M -$19.6M -$22.9M
DBVT
Sector
Market Cap
$65.4M
$43.9M
Price % of 52-Week High
29.81%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-66.77%
-29.11%
Beta (5-Year)
0.642
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $3.31
200-day SMA
Sell
Level $4.89
Bollinger Bands (100)
Sell
Level 3.15 - 4.35
Chaikin Money Flow
Sell
Level -10.5M
20-day SMA
Sell
Level $3.39
Relative Strength Index (RSI14)
Sell
Level 46.59
ADX Line
Sell
Level 12.43
Williams %R
Neutral
Level -74.4318
50-day SMA
Sell
Level $3.43
MACD (12, 26)
Sell
Level -0.04
25-day Aroon Oscillator
Buy
Level 36
On Balance Volume
Neutral
Level 19.9M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Stock Forecast FAQ

In the current month, DBVT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DBVT average analyst price target in the past 3 months is --.

  • Where Will DBV Technologies SA Stock Be In 1 Year?

    According to analysts, the consensus estimate is that DBV Technologies SA share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About DBV Technologies SA?

    Analysts are divided on their view about DBV Technologies SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that DBV Technologies SA is a Sell and believe this share price will drop from its current level to --.

  • What Is DBV Technologies SA's Price Target?

    The price target for DBV Technologies SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is DBVT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for DBV Technologies SA is a Buy. 0 of 0 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of DBVT?

    You can purchase shares of DBV Technologies SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase DBV Technologies SA shares.

  • What Is The DBV Technologies SA Share Price Today?

    DBV Technologies SA was last trading at $3.22 per share. This represents the most recent stock quote for DBV Technologies SA. Yesterday, DBV Technologies SA closed at $3.19 per share.

  • How To Buy DBV Technologies SA Stock Online?

    In order to purchase DBV Technologies SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 3.98% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 8.75% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 3.58% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock